Literature DB >> 10798553

Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria.

Ludmila Boyanova, Irina Stancheva1, Zoya Spassova1, Nikolai Katzarov1, Ivan Mitov, Radka Koumanova1.   

Abstract

The aim of this study was to evaluate the primary and combined resistance of Helicobacter pylori against four antimicrobial agents by a screening agar method (SAM) and a modified disk diffusion method (MDDM) alone and in combination. Pre-treatment H. pylori isolates from 192 consecutive H. pylori-positive patients at three hospitals in Sofia were investigated. MDDM was performed with disks containing metronidazole (5 microg), clarithromycin (15 microg) or erythromycin (15 microg), ciprofloxacin (5 microg) and tetracycline (30 microg). Resistance was determined by an inhibitory zone of <16 mm for metronidazole and < or =30 mm for other agents tested. The cut-off concentrations used to define resistance by SAM were: metronidazole >8 mg/L, clarithromycin >2 mg/L, tetracycline >4 mg/L and ciprofloxacin >1 mg/L. Primary resistance rates in H. pylori were: metronidazole 28.6%, clarithromycin 9.7%, metronidazole + clarithromycin 2.8%, ciprofloxacin 3.9%, metronidazole + ciprofloxacin 2.3%, tetracycline 1.9% and metronidazole + tetracycline 1.2%. Among metronidazole-resistant isolates, combined resistance to clarithromycin, ciprofloxacin and tetracycline was present in 11.4% (5 of 44 strains), 8.3% (3 of 36) and 4.9% (2 of 41), respectively. Two strains exhibited triple resistance to macrolides, metronidazole and either ciprofloxacin or tetracycline. Three tetracycline-resistant strains were detected in 1999; however, resistance rates to other agents were relatively stable during the 6 years. Primary H. pylori resistance to metronidazole is moderate and resistance to clarithromycin and to ciprofloxacin is considerable in comparison with results in most other countries. The alarming appearance of strains harbouring combined resistance or multiresistance provides the motivation for continued surveillance of H. pylori at global, national and regional levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798553     DOI: 10.1099/0022-1317-49-5-415

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  15 in total

1.  Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran.

Authors:  Tahereh Falsafi; Fatemeh Mobasheri; Farahnaz Nariman; Mehri Najafi
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran.

Authors:  Amin Talebi Bezmin Abadi; Tarang Taghvaei; Ashraf Mohabbati Mobarez; Beth M Carpenter; D Scott Merrell
Journal:  J Microbiol       Date:  2011-12-28       Impact factor: 3.422

3.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

4.  Integrative computational protocol for the discovery of inhibitors of the Helicobacter pylori nickel response regulator (NikR).

Authors:  Aldo Segura-Cabrera; Xianwu Guo; Arturo Rojo-Domínguez; Mario A Rodríguez-Pérez
Journal:  J Mol Model       Date:  2011-03-01       Impact factor: 1.810

5.  Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci.

Authors:  Daiva Dailidiene; M Teresita Bertoli; Jolanta Miciuleviciene; Asish K Mukhopadhyay; Giedrius Dailide; Mario Alberto Pascasio; Limas Kupcinskas; Douglas E Berg
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori.

Authors:  D H Kwon; J J Kim; M Lee; Y Yamaoka; M Kato; M S Osato; F A El-Zaatari; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marco Berning; Arnoud H M Van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.

Authors:  Jacques Tankovic; Christine Lascols; Quentin Sculo; Jean-Claude Petit; Claude-James Soussy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997-2001).

Authors:  G Gościniak; B Iwańczak; A Przondo-Mordarska; J Grabińska; F Iwańczak
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

10.  16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marcel R de Zoete; Niek L A Arents; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.